~~<i id='A56297B23A'><strike id='A56297B23A'><tt id='A56297B23A'><pre id='A56297B23A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：explore 2025-09-30 17:29:05 - browse：15627

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Bird flu outbreak in cows is latest avian flu curveball

entertainment

hotspot

entertainment

focus

Wikipedia

BusinesswireviaAPTheFoodandDrugAdministrationwarnedconsumersMondaytonotuseCueHealth’sat-homeCovid-19

WSS

Investment in vaccine development is lagging, report finds

H5N1 bird flu found in pasteurized milk: what we know

Bird flu outbreak in cows is latest avian flu curveball

Biogen walks away from Aduhelm, years after polarizing approval

Cholera vaccine supply gets boost as demand surges globally

Getting Alzheimer's drug Leqembi to patients can be a challenge

leisure time

knowledge

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare drug price negotiation legal challenge met with skepticism

In age of alternative facts, a scholarly course on calling out crap

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Hepatitis C has a cure — but many Americans still lack access to it

H5N1 bird flu virus started spreading in cows in Texas in December

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage insurers face 0.2% cut to 2025 payments

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage insurers face 0.2% cut to 2025 payments

hotspot

Medicare Advantage insurers face 0.2% cut to 2025 payments

Merck, Johnson & Johnson CEOs will testify on high drug prices

White House pharmacy plagued with problems, investigation finds

Getting Alzheimer's drug Leqembi to patients can be a challenge

Reconstructing family trees of blood cells may help predict disease

Readout Newsletter: The latest on Novavax, Merck, Bluebird

hotspot

entertainment

focus

Wikipedia